Cyclerion reports $44.1M net loss in 2022; cash $13.4M; evaluating options for zagociguat

Cyclerion Therapeutics, Inc.

Cash, equivalents & restricted cash $13.4M at Dec 31, 2022, down from $20.4M at Sep 30, 2022.
Net loss $44.1M for FY 2022 vs $51.6M in FY 2021; R&D spend $31.5M, G&A $14.5M.
Met with FDA in Q4 2022; filed for Orphan Drug Designation for zagociguat in MELAS.
Refined Phase 2b design for zagociguat; manufactured drug product to support the study.
Company actively evaluating capital, capabilities, or transactions to advance pipeline and maximize value.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cyclerion Therapeutics, Inc. reported the full year 2022 results: net income approximately $44.1 million.

Period: the full year 2022
Net income: approximately $44.1 million
Result: reported results

Exact text from the filing

Net loss was approximately $44.1 million for the full year 2022, as compared to $51.6 million for the full year 2021.

View on SEC.gov

Browse all earnings releases →

Cyclerion Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-009221

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.